Trial Details
COMPLETEDBasic Information
| Clinical ID | c2690 |
|---|---|
| Identifier | NCT03104413 |
| Trial Title | A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment |
| Trial URL | Visit Original Page |
Study Information
| Study Results | YES |
|---|---|
| Conditions | Crohn's Disease |
| Interventions | DRUG: placebo for risankizumab IV|DRUG: risankizumab SC|DRUG: risankizumab IV |
Participant Information
| Sponsor | AbbVie |
|---|---|
| City | Phoenix |
| Country/Region | United States |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | CHILD, ADULT, OLDER_ADULT |
Study Design
| Study Type | INTERVENTIONAL |
|---|---|
| Phase | PHASE3 |
Time Information
| Start Date | 2017-12-18 |
|---|---|
| Primary Completion Date | 2020-11-30 |
| Completion Date | 2021-05-19 |